Takeda Demonstrates Progress in Advancing Health Economics at ISPOR 2021

Health economics (HE) analyzes the costs and consequences of healthcare interventions to evaluate their effects on patient-related clinical, humanistic, and economic outcomes.

At Takeda, we are committed to advancing the principles and practice of HE by collaborating with strategic partners to identify innovative and bold solutions that help ensure patients have access to our medicines. To achieve this, we partner globally to translate the value of our therapies to payers across all markets with the ultimate goal of expanding access while minimizing the time to reimbursement. We believe that the value of HE goes far beyond coverage and reimbursement decisions and should be considered throughout a treatment’s lifecycle, starting in the early stages of development. Thus, we apply HE principles cross-functionally to influence the design of clinical trials, the planning of evidence generation and the approach to prioritizing our research and pricing our medicines – all with the goal of delivering better health outcomes for patients.

From Tuesday, November 30 through Friday, December 3, Takeda will be showcasing the company’s leadership in HE at Virtual ISPOR Europe 2021, the leading European conference for HE and outcomes research (HEOR), bringing together global leaders for discussion and dissemination of the latest trends in healthcare. At this year’s European conference, Takeda will feature 11 company-sponsored presentations, including analyses in leukemia, lymphoma and non-small cell lung cancer (NSCLC), that introduce new findings focused on improving health outcomes for patients while ensuring sustainability and cost-effectiveness for health systems. Please see below for the full list of presentations.

We look forward to joining the HEOR community at this year’s conference to work towards our shared vision of pursuing solutions to improve decision making, and ultimately, health outcomes for patients globally.

PODIUM PRESENTATIONS

Abstract P54: Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adult Patients with Severe Hemophilia Α in China

Authors: Gu C; Jiao Z; Huang H; Han Y

Session: Methods for Decision Modelling and Economic Evaluation

Abstract P74: Treatment Patterns and Outcomes in Patients with Acute Myeloid Leukaemia (AML) in England: A Cancer Analysis System (CAS) Registry Retrospective Cohort

Authors: Caseby S; Cranmer H; Ohlmeyer V; Groucott J; Eaton J; Podkonjak T; Lambova A; Adamson E; Kearns I

Session: Using Real World Evidence to Predict Risks of Adverse Outcomes and Disease Progression

POSTERS 

Abstract POSA101: Modeling Approaches in Cost-Effectiveness Analyses of Cell Therapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Authors: Hernandez L, Martin A, Brouwer E, Chun D, Cheng L, Bernhardt A

Abstract POSA300: Combining Clinical Trial and Real-World Evidence (RWE) Data in the Assessment of Public Health Impact in Health Technology Assessment (HTA) Evaluations

Authors: Leleu H, Nucit A, Lefevre C, Salvignol O, Grenier B, Coulibaly C, Jolivel R, Blachier M

Abstract POSA387: Healthcare Resource Utilization and Direct Medical Costs in French Patients Receiving Treatment for Hypogammaglobulinemia: A National Cohort Study

Authors: Borget I, Lefevre G, Maherzi C, Lefevre C, Hennaoui M, Nucit A, Dayde F, Grenier B, Schmidt A, Lennon H, Mahlaoui N

Abstract POSB16: Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Using Final Results from ALTA 1L and ALEX Trials

Authors: Cranmer H, Kay S, Lin M, Cazzato S

Abstract POSB24: Long-Term Survival Associated with Next-Generation Sequencing (NGS) Versus Standard Diagnostic Tests to Detect Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Variants in Non-Small-Cell Lung Cancer (NSCLC): A Decision-Analytic Model

Authors: Hernandez L, Walton L, Churchill E

Abstract POSB135: Budget Impact Analysis of First-Line Treatment for ALK-Positive (ALK+) Advanced NSCLC In Italy

Authors:  Urbinati D, La Malfa P, Demma F, Viti R, Cranmer H, Hernandez L

Abstract POSB151: Leading First-Line Treatment Option for ALK+ NSCLC in Portugal

Authors: Monteiro S, Labisa P, Fragoso J, Ferreira C, Cochado S

Abstract POSC5: Adjusting for Subsequent Therapies in the TOURMALINE-MM1 Study Shows Improvement in Overall Survival

Authors: Ramasamy K, Kumar A, Cranmer H, Wang B, Dabora J, Labotka R

Abstract POSC49: The Cost-Effectiveness of First-Line Treatment for Systemic Anaplastic Large Cell Lymphoma (sALCL) in France

Authors: Chaker O, Nucit A, Salvignol O, Thoren AC, Cranmer H, Coulibaly C, Chevalier J, Borget I